Spots Global Cancer Trial Database for b cell lymphoma
Every month we try and update this database with for b cell lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN1 | NCT04418141 | Advanced Solid ... B Cell Lymphoma | CN1 | 18 Years - 75 Years | Curon Biopharmaceutical (Australia) Co Pty Ltd | |
| Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma | NCT05412290 | B Cell Lymphoma Aggressive Lymp... Diffuse Large B... High-grade B-ce... Transformed Lym... Follicular Lymp... | Mosunetuzumab | 18 Years - | Washington University School of Medicine | |
| Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma | NCT01593696 | ALL B Cell Lymphoma Leukemia Large Cell Lymp... Non-Hodgkin Lym... | Anti-Cluster of... | 1 Year - 30 Years | National Institutes of Health Clinical Center (CC) | |
| Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma | NCT00880867 | B Cell Lymphoma T Cell Lymphoma | Poly-ICLC | 18 Years - | Nevada Cancer Institute | |
| BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I) | NCT04018248 | Diffuse Large B... Follicular Lymp... Chronic Lymphoc... Small Lymphocyt... B Cell Lymphoma Marginal Zone L... Waldenstrom Mac... Peripheral T Ce... | BR101801 (Phase... BR101801 (Phase... | 18 Years - | Boryung Pharmaceutical Co., Ltd | |
| Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies | NCT03366350 | Acute Lymphobla... B Cell Lymphoma | Allogeneic hema... | - 70 Years | Wuhan Sian Medical Technology Co., Ltd | |
| A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma | NCT03398967 | B Cell Leukemia B Cell Lymphoma | Universal Dual ... | 12 Years - 70 Years | Chinese PLA General Hospital | |
| CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma. | NCT03146533 | B Cell Lymphoma | Fludarabine Cyclophosphamid... CD19 CART | 18 Years - 70 Years | Shenzhen Second People's Hospital | |
| A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma | NCT03398967 | B Cell Leukemia B Cell Lymphoma | Universal Dual ... | 12 Years - 70 Years | Chinese PLA General Hospital | |
| Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma | NCT05412290 | B Cell Lymphoma Aggressive Lymp... Diffuse Large B... High-grade B-ce... Transformed Lym... Follicular Lymp... | Mosunetuzumab | 18 Years - | Washington University School of Medicine | |
| Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies | NCT04008251 | Acute Lymphobla... B Cell Lymphoma | Second generati... | 14 Years - 70 Years | Wuhan Sian Medical Technology Co., Ltd | |
| Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma | NCT03995147 | B Cell Lymphoma Lymphoma Lymphoma, B-Cel... Diffuse Large B... High-grade B-ce... | Pembrolizumab R-CHOP Protocol | 18 Years - | University of Chicago | |
| Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype | NCT00001572 | B Cell Lymphoma Follicular Lymp... Neoplasm | Id-KLH Vaccine QS-21 (Stimulat... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study Analysis | NCT06058858 | Cytomegalovirus... Acute Leukemia B Cell Lymphoma | 1 Year - 100 Years | Assistance Publique - Hôpitaux de Paris | ||
| The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma | NCT03101709 | B Cell Lymphoma | Cyclophosphamid... Fludarabine CART-19 | 18 Years - 70 Years | Henan Cancer Hospital | |
| A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients | NCT03670888 | B Cell Lymphoma | JHL1101 Rituximab | 18 Years - 75 Years | JHL Biotech, Inc. | |
| CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies | NCT04156178 | B Cell Lymphoma B Cell Leukemia | CD20-CD19 cCAR ... | - | iCell Gene Therapeutics | |
| Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma | NCT06415708 | B Cell Lymphoma | Obinutuzumab Co... | 18 Years - | Institute of Hematology & Blood Diseases Hospital, China | |
| A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies | NCT03999697 | Diffuse Large B... Follicular Lymp... Primary Cutaneo... Extranodal Marg... Mantle Cell Lym... Plasma Cell Neo... B Cell Lymphoma | Autologous chim... | 3 Years - 70 Years | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | |
| Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy | NCT00038571 | Lymphoma, B-Cel... | PS341 (Bortezom... | 17 Years - | M.D. Anderson Cancer Center | |
| Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies | NCT03366324 | Acute Lymphobla... B Cell Lymphoma | Second generati... Hematological s... | - 70 Years | Wuhan Sian Medical Technology Co., Ltd | |
| Induced-T Cell Like NK Cells for B Cell Malignancies | NCT04747093 | B Cell Leukemia B Cell Lymphoma B-cell Acute Ly... B-cell Lymphoma... B-cell Lymphoma... | CAR-ITNK cells | 18 Years - 65 Years | Nanfang Hospital, Southern Medical University | |
| Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma. | NCT03929107 | B Cell Lymphoma | Interleukin-7 a... | 18 Years - 75 Years | First Affiliated Hospital of Zhejiang University | |
| A Study of SHR-A1912 for Injection in Patients With B Cell Lymphomas | NCT05113069 | B Cell Lymphoma | SHR-A1912 | 18 Years - | Shanghai Hengrui Pharmaceutical Co., Ltd. | |
| ThisCART19A for B-NHL Relapsed After Auto-CAR T | NCT05691153 | CAR B Cell Lymphoma Relapsed Non-Ho... | ThisCART19A wit... ThisCART19A wit... | 18 Years - 75 Years | The First Affiliated Hospital of Soochow University | |
| Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma | NCT06180174 | B Cell Lymphoma Non Hodgkin Lym... | MC-1-50 | 18 Years - | Chongqing Precision Biotech Co., Ltd | |
| Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma | NCT06415708 | B Cell Lymphoma | Obinutuzumab Co... | 18 Years - | Institute of Hematology & Blood Diseases Hospital, China | |
| Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma | NCT00880867 | B Cell Lymphoma T Cell Lymphoma | Poly-ICLC | 18 Years - | Nevada Cancer Institute | |
| A Study of SHR-A1912 for Injection in Patients With B Cell Lymphomas | NCT05113069 | B Cell Lymphoma | SHR-A1912 | 18 Years - | Shanghai Hengrui Pharmaceutical Co., Ltd. | |
| A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma | NCT06213311 | B Cell Lymphoma | Glofitamab Obinutuzumab Axi-cel | 18 Years - | M.D. Anderson Cancer Center | |
| CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma. | NCT03146533 | B Cell Lymphoma | Fludarabine Cyclophosphamid... CD19 CART | 18 Years - 70 Years | Shenzhen Second People's Hospital | |
| Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas | NCT02247609 | B-cell Lymphoma... | Anti-CD19 CAR T... | 18 Years - | Peking University | |
| A Combination of Rituximab and Varlilumab Immunotherapy in Patients With B-cell Lymphoma | NCT03307746 | B Cell Lymphoma | Varlilumab | 16 Years - | University Hospital Southampton NHS Foundation Trust | |
| Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas | NCT05415098 | Nasopharyngeal ... Castrate Resist... Gastric Cancer Ovarian Clear C... Mesothelioma Sarcoma Non Hodgkin Lym... B Cell Lymphoma Epithelioid Sar... | APG-5918 | 18 Years - | Ascentage Pharma Group Inc. | |
| Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study Analysis | NCT06058858 | Cytomegalovirus... Acute Leukemia B Cell Lymphoma | 1 Year - 100 Years | Assistance Publique - Hôpitaux de Paris | ||
| Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma | NCT00169468 | B Cell Lymphoma | Rituximab -CHOP... | 18 Years - 80 Years | Lymphoma Study Association | |
| CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies | NCT04088864 | B Cell Lymphoma Acute Lymphobla... Lymphoma | Fludarabine Cyclophosphamid... Autologous CD22... | 1 Year - 30 Years | Stanford University | |
| Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines | NCT00001512 | B Cell Lymphoma Follicular Lymp... Lymphoma | Id-KLH Vaccine GM-CSF | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study in Leukemia Patients With Karonudib | NCT04077307 | Leukemia | Karonudib | 18 Years - 75 Years | Thomas Helleday Foundation | |
| CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial. | NCT02132624 | B Cell Lymphoma B Cell Leukemia | Autologous 3rd ... | 18 Years - | Uppsala University | |
| CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia | NCT03854994 | B Cell Lymphoma B-cell Acute Ly... | Anti-CD19 CAR-T... | 18 Years - | Yan'an Affiliated Hospital of Kunming Medical University | |
| Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma | NCT02898259 | B Cell Lymphoma Lymphoma | Ixazomib Lenalidomide Rituximab | 18 Years - | Case Comprehensive Cancer Center | |
| Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL) | NCT01435720 | Multiple Myelom... Multiple Myelom... Mantle Cell Lym... Diffuse Large B... Other B Cell Ly... Plasma Cell Leu... | SNS01-T SNS01-T SNS01-T SNS01-T | 18 Years - | Senesco Technologies, Inc. | |
| Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype | NCT00001572 | B Cell Lymphoma Follicular Lymp... Neoplasm | Id-KLH Vaccine QS-21 (Stimulat... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study) | NCT06002659 | B-cell Lymphoma | CAR20(NAP)-T Cyclophosphamid... Fludarabine | - | Uppsala University | |
| a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma | NCT04782193 | B Cell Lymphoma | CD19 and CD22 t... | 2 Years - 75 Years | Chongqing Precision Biotech Co., Ltd | |
| A Study of SHR-A1912 for Injection in Patients With B Cell Lymphomas | NCT05113069 | B Cell Lymphoma | SHR-A1912 | 18 Years - | Shanghai Hengrui Pharmaceutical Co., Ltd. | |
| Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia | NCT04289220 | B Cell Lymphoma B-cell Acute Ly... | Anti-CD19 CAR-T... | 18 Years - 70 Years | Yan'an Affiliated Hospital of Kunming Medical University | |
| Treatment of Aggressive Localized Lymphoma | NCT00841945 | B Cell Lymphoma | rituximab doxorubicin vincristine prednisone radiotherapy | 18 Years - 75 Years | French Innovative Leukemia Organisation | |
| CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies | NCT04156243 | B Cell Lymphoma B Cell Leukemia | CD19 CARvac T c... | - | iCell Gene Therapeutics | |
| A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma | NCT06213311 | B Cell Lymphoma | Glofitamab Obinutuzumab Axi-cel | 18 Years - | M.D. Anderson Cancer Center | |
| Lower Dose Decitabine Based Therapy in Patients With Refractory and/or Chemotherapy Resistant Solid Tumors or B Cell Lymphomas | NCT01799083 | Solid Tumors B Cell Lymphoma | Decitabine cytokine-induce... | 18 Years - 85 Years | Chinese PLA General Hospital | |
| Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma | NCT01593696 | ALL B Cell Lymphoma Leukemia Large Cell Lymp... Non-Hodgkin Lym... | Anti-Cluster of... | 1 Year - 30 Years | National Institutes of Health Clinical Center (CC) | |
| A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma | NCT00001271 | B Cell Lymphoma | IgG-RFB4-SMPT-d... | - | National Institutes of Health Clinical Center (CC) | |
| Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype | NCT00001572 | B Cell Lymphoma Follicular Lymp... Neoplasm | Id-KLH Vaccine QS-21 (Stimulat... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype | NCT00001572 | B Cell Lymphoma Follicular Lymp... Neoplasm | Id-KLH Vaccine QS-21 (Stimulat... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL | NCT00586391 | B Cell Lymphoma Chronic Lymphoc... Acute Lymphocyt... | CD19CAR-28-zeta... Ipilimumab | - | Baylor College of Medicine | |
| Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies | NCT03366324 | Acute Lymphobla... B Cell Lymphoma | Second generati... Hematological s... | - 70 Years | Wuhan Sian Medical Technology Co., Ltd | |
| Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies | NCT04007978 | B Cell Lymphoma Acute Lymphobla... | Third generatio... | 14 Years - 70 Years | Wuhan Union Hospital, China | |
| CD19-targeting CAR T Cells for B Cell Lymphoma | NCT02547948 | B Cell Lymphoma | CD19-targeting ... | 18 Years - 80 Years | Fuda Cancer Hospital, Guangzhou | |
| Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors | NCT03302403 | B Cell Lymphoma B Cell Leukemia Myeloma Hepatocellular ... Pancreatic Carc... Adenocarcinoma ... | CAR-CD19 T cell CAR-BCMA T cell CAR-GPC3 T cell CAR-CLD18 T cel... Fludarabine Cyclophosphamid... | 18 Years - 75 Years | First Affiliated Hospital of Wenzhou Medical University | |
| A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies | NCT00741871 | Lymphoma, Malig... Hodgkin's Lymph... B Cell Lymphoma | SB1518 | 18 Years - | S*BIO | |
| Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma | NCT01148108 | Mantle Cell Lym... B Cell Lymphoma Multiple Myelom... | Canfosfamide HC... | 18 Years - | Telik | |
| A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma | NCT03166878 | B Cell Leukemia B Cell Lymphoma | UCART019 | 12 Years - 75 Years | Chinese PLA General Hospital | |
| Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas | NCT05415098 | Nasopharyngeal ... Castrate Resist... Gastric Cancer Ovarian Clear C... Mesothelioma Sarcoma Non Hodgkin Lym... B Cell Lymphoma Epithelioid Sar... | APG-5918 | 18 Years - | Ascentage Pharma Group Inc. | |
| CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies | NCT04156243 | B Cell Lymphoma B Cell Leukemia | CD19 CARvac T c... | - | iCell Gene Therapeutics | |
| A Phase II Study of the FIL on Elderly Frail Patients With DLBCL | NCT02955823 | Diffuse Large B... | Rituximab-Dexam... | 70 Years - | Fondazione Italiana Linfomi - ETS | |
| CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies | NCT02965092 | Acute Lymphobla... B Cell Lymphoma | Second generati... | - 70 Years | Wuhan Sian Medical Technology Co., Ltd | |
| Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma | NCT03258047 | B Cell Lymphoma | CAR-T | 18 Years - | First Affiliated Hospital of Zhejiang University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
